Johnson & Johnson stock gets a fresh analyst lift. Dividend and guidance support the long-term story

Johnson & Johnson stock trades near recent highs after Guggenheim lifted its price target, while updated guidance and a growing dividend underline the healthcare giant's income and defensive appeal for investors.

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 2:21 p.m. ET.

Johnson & Johnson (ISIN US4781601046) is trading close to recent highs on the New York Stock Exchange after a price-target increase from Guggenheim highlighted continued analyst confidence in the healthcare group, as reported by Transcript Daily. The report notes that shares recently moved higher after Guggenheim lifted its price target on JNJ to $270 and reiterated a buy rating, adding to the company's existing fiscal 2026 earnings guidance and dividend profile.

Guggenheim lifts target as JNJ trades near $258

The latest analyst catalyst came from a Guggenheim call in which the firm raised its 12-month price target on Johnson & Johnson stock from $266 to $270 and maintained a buy recommendation, according to the detailed coverage by Transcript Daily. In the same session, JNJ traded as high as $258.58 and last changed hands at approximately $258.24, with volume of around 8.4 million shares, slightly below its average of roughly 8.5 million shares in regular NYSE trading hours.

A separate market-data view shows Johnson & Johnson quoted at $258.42 at the June 29, 2026 close in New York, with the company carrying a market capitalization of about $621.9 billion and a trailing price-to-earnings ratio near 29.6, according to figures compiled by TradingKey. That price level is broadly in line with the $258.51 last close and the analyst average target of about $257.50 shown on the consensus overview from MarketScreener, suggesting Wall Street expectations cluster close to the current market quote.

Guidance, consensus and institutional positioning

The broader earnings backdrop for Johnson & Johnson remains defined by its fiscal 2026 guidance for earnings per share in a range of $11.45 to $11.65, with sell-side forecasts centered around $11.57 per share for the current fiscal year, according to data cited in the analyst-upgrade coverage on Transcript Daily. On valuation, that earnings path implies a forward price-to-earnings multiple in the low-20s based on the latest share price around the mid-$250s, placing JNJ at a premium to some diversified healthcare peers but consistent with its history as a defensive, large-cap name.

Consensus indicators reviewed by MarketScreener show an overall analyst stance of ‘Outperform’ on Johnson & Johnson, based on coverage from 23 analysts and an average price target close to $257.50. That aggregate view lines up with the Guggenheim increase to $270 on the bullish side and underscores that, while individual calls may differ, Wall Street broadly expects the stock to deliver total returns modestly above the current price with a combination of earnings growth and dividends.

Recent institutional-ownership data also reinforce the stock's role in large portfolios. An update from MarketBeat highlights that Fort Washington Investment Advisors Inc. OH trimmed its holdings in Johnson & Johnson by about 29.1% in the first quarter of 2026, selling roughly 435,900 shares while still retaining more than 1.06 million shares valued at around $260.2 million at period end. The position remains the fund's 12th largest, and broader data referenced in the upgrade report indicate institutional investors collectively own close to 70% of JNJ's float, a level typical for large S&P 500 healthcare constituents.

Alongside the analyst narrative, Johnson & Johnson's dividend history remains central to its investor appeal. The company recently lifted its quarterly dividend to $1.34 per share from $1.30, translating into an annualized payout of $5.36 and a yield near 2.1% at recent prices, based on figures summarized in the same Transcript Daily coverage. With a payout ratio close to 62% of earnings, JNJ continues to balance income distribution with retained cash for research, development and acquisitions, a profile many income-focused investors seek in defensive healthcare stocks.

Pharmaceuticals and medical devices as growth pillars

Johnson & Johnson's operating model rests on a diversified healthcare platform that spans prescription pharmaceuticals, medical devices and consumer health products, with the first two segments now driving most of the company's revenue and profit. In pharmaceuticals, JNJ markets treatments across oncology, immunology, neuroscience and infectious diseases, relying on a portfolio of branded drugs protected by patents and supported by large-scale clinical programs. This mix gives the company exposure to long-duration therapy areas where demand tends to be steady even through economic cycles, a key reason large funds treat JNJ as a defensive holding.

On the medical-technology side, Johnson & Johnson manufactures and distributes a broad range of devices used in surgery, orthopedics and cardiovascular care, among other specialties. These products are sold primarily to hospitals and clinics, often via long-term contracts or preferred-supplier agreements that embed the company deeply into clinical workflows. The scale of these businesses, combined with JNJ's global footprint, helps smooth revenue across geographies and procedure categories, even as individual product lines rise or fall with innovation cycles and competitive dynamics.

Research and development spending underpins both growth engines. Johnson & Johnson consistently allocates a significant portion of its operating budget to R&D, funding clinical trials, device innovation and platform technologies that can be deployed across multiple indications. While specific pipeline items are subject to regulatory risk, the breadth of the portfolio lowers reliance on any single asset and gives the company latitude to reallocate capital as market conditions change or new science emerges. For investors comparing large-cap healthcare names, this combination of diversification and scale is often a decisive factor.

JNJ stock price and trading snapshot

As of June 29, 2026, Johnson & Johnson stock closed at $258.42 in regular NYSE trading, based on consolidated price data from TradingKey. That quote places the company's equity value at roughly $621.9 billion and reflects a trailing price-to-earnings ratio of about 29.6, positioning JNJ firmly among the largest healthcare constituents in major US indices and underscoring its role as a core holding in many diversified portfolios.

Johnson & Johnson stock at a glance

• Company: Johnson & Johnson Inc.
• ISIN: US4781601046
• Ticker: JNJ
• Exchange: New York Stock Exchange (primary listing)
• Price (as of June 29, 2026, 4:00 p.m. ET): $258.42 USD
• Market cap: $621.9 billion (as of June 29, 2026)
• Sector / Industry: Health care - Pharmaceuticals, medical devices and consumer health
• Index membership: Major US large-cap health care and broad-market indices
• Next earnings date: not yet officially scheduled

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.